For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Noriaki Ishida, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 <u>http://www.daiichisankyo.com</u>

Daiichi Sankyo Announces New 5-year Business Plan

Tokyo, Japan (March 22, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a new 5-year Business Plan, which will span from April 1, 2013 through March 31, 2018.

Overview of new 5-year Business Plan

1. Management Goals for FY2017

Within the period of the new 5-year plan, we will work toward two major objectives in order to realize sustainable growth and overcome the "patent cliff" owing to expiration of the exclusive patent rights to Olmesartan, our mainstay anti-hypertensive agent, in the US and Europe.

Sustainable revenue growth with improved profitability

We will achieve sustainable growth by maximum utilization of the business foundation created during the 1st and 2nd Mid-term Plans and improve profitability.

- Over 5% revenue CAGR (FY2012 to FY2017).
- Over 15% operating profit margin by FY2017.
- Over 10% ROE.
- EPS of 150 yen.
- Stable dividends and increased shareholder value.

Enhancement and growth of Group business centering on Daiichi Sankyo and Ranbaxy (creation of synergy)

In addition to Daiichi Sankyo and Ranbaxy achieving high growth and improved profitability in their respective businesses, we aim to create additional synergies between the two companies, not only in the areas of sales and production where initiatives have already begun, but across the various processes of the value chain, including the opening of new markets and the creation of high added-value products.

- Strengthen business in key markets (Japan, India, and USA) and emerging markets.
- Establish flexible corporate structure to navigate changes in business environment.

2. Core Strategies

Strengthen innovative pharmaceutical portfolio and R&D pipeline

- Maximize cash flows from olmesartan.
- Maximize sales potential for antiplatelet agent prasugrel and oral direct factor Xa inhibitor edoxaban.
- Grow high potential products in Japan.
- Enhance pipeline following launch of edoxaban.
- Expand presence in biologics/biosimilar business.
- Acquire external assets.

Develop competitive businesses to address diverse local needs

- Expand business in emerging countries through Ranbaxy and the Daiichi Sankyo business in ASCA.*
- Maintain top share in the injectable iron business in the USA through launch of Injectafer.
- Increase profitability of generic and vaccine businesses in Japan.

Transition to a low-cost operating framework

- Establish organizational structure to address diverse needs in each region.
- Establish global supply chain system for continuous cost reduction.
- Strengthen revenue management at business unit and regional levels.

3.	Numerical Targets for FY2017
----	------------------------------


	FY 2017 (Target)	FY2012 (Latest Estimate)
Net Sales	1.3 trillion yen	990 billion yen
Cost of Goods	37%	31%
SG&A Expenses	48%	59%
(R&D expenses)	(14%)	(19%)
Operating Income	200 billion yen	100 billion yen
	(15%)	(10%)
Profit After Tax	110 billion yen	50 billion yen


FY2017 forecasted exchange rate: 1 USD = 90 yen; 1 EUR = 120 yen


*ASCA: Refers to Daiichi Sankyo Group companies in Asia, South and Central America

For more information, please see the presentation materials for the announcement of the new 5-year Business Plan on our website, <u>http://www.daiichisankyo.com/ir/archive/imm/year/list_2012.html</u>












2nd 3-ye	ar Plan	: Quan	titativ	ve Eval		Daiichi-
	FY2012 Target under the 2 nd MTP	FY2012 LE	Difference		Main Factors	
					Olmesartan/Effient in US/EU	-31
		990	-160	Daiichi Sankyo	Others in US/EU	-15
Net Sales	1,150				Japan Business, etc.	+12
	1,150				Forex impact	-43
				Ranbaxy	Impact from FDA issues	-52
					Forex impact	-31
COGs (/Net Sales)	343 (29.8%)	307 (31.0%)	-36 (1.2%)			
SG&A expenses (/Net Sales)	627 (54.5%)	583 (58.9%)	-44 (4.4 %)	Forex impa	ct -38	
R&D expenses (/Net Sales)	200 (17.4%)	188 (19.0%)	-12 (1.6%)			
Operating Income (/Net Sales)	180 (15.7%)	100 (10.1%)	-80 (- 5.6 %)			
_ USD/yen	90	81.26				
Forex EUR/yen	130	105.39				










rical Targets	5	
	FY2012 LE	FY2017 (Target)
Net Sales	Yen 990 bn	Yen 1,300 bn
COGs	31%	37%
SG&A expenses (R&D expenses)	59% (19%)	48% (14%)
Operating Income (/Net Sales)	Yen 100 bn (10%)	Yen 200 bn (15%)
Profit after Tax	Yen 50 bn	Yen 110 bn
Forex USD/Yen EUR/Yen		90 130
























Invest	in can	didates to b	e growth drivers for the future
Project	Stage	Indication	Product Profile
Tivantinib	P3	Hepatocellular cancer Colorectal cancer	 Met inhibitor/oral PFS improved statistically in Ph2 Co-developed with ArQule
DS-5565	P2	Diabetic peripheral neuropathic pain	• α2δ ligand/oral • In-house compound
U3-1287	P2	Breast cancer Non small cell lung cancer	 HER3 antibody/iv Originated by U3 Pharma
PLX-3397	P2	Cancer	 Kinase inhibitor for FMS, Kit and Flt3- ITD/oral Indications: AML, Glioblastoma, breast cancer, etc.













wth St	trategy	in Major Markets
		owth in developed markets inable growth in emerging markets
CAGR	FY2017 Target(Yen bn)	Mid term growth strategy
4%	630 bn	 To become No.1 company by sales with focus on innovative products and expanding market share Achieve long-term sustainable growth through lifecycle management and enhancing the product portfolio
2%	290 bn	• Expand Business through DSI, Luitpold and Ranbaxy, with each of them excelling in their respective areas
3%	90 bn	 Shift Olmesartan business from mono to combination product Grow Efient business; successfully launch Edoxaban
15%	290 bn	 Further expand business in India, East Europe, CIS and Africa etc. Expand the Olmesartan business, strengthen presence with Prasugrel and successful launch of edoxaban in China Maximize the Olmesartan business in ASCA countries and successfully launch Edoxaban
	Lbstant CAGR 4% 2% 3%	Steady gr Ibstantial susta CAGR FY2017 Target(Yen br) 4% 630 bn 2% 290 bn 3% 90 bn





Key products for No.1 company in Japan						
		Strategy	Market Size (Yen bn) MAT 2013/2*			
1	Olmesaratan	Top sales in ARB market with strong efficacy and sustainability backed by Japanese data	590			
2	Memary	Top share in mono/combination therapy with the unique MOA of NMDA antagonist	150			
3	Nexium	Top share as the best-in-class PPI product cooperating with AstraZeneca	220			
4	Prasugrel	Gain market share as a new standard therapy of anti- platelet for Japanese patients in heart/brain area	310**			
5	Lixiana	Standard therapy in DVT-OS, Best-in-class drug in AF and VTE	43			
6	Ranmark/	Top share as the first anti-RANKL antibody in world cooperating with AstraZeneca	17			
0	denosumab (osteoporosis)	Expand market share as a new therapy with good efficacy and practicality	200			
7	Tenelia/ canagliflozin	Establish strong position in diabetes area cooperating with Mitsubishi Tanabe	320			



Pursue sales growth with increased profit contribution					
Business Unit Strategy					
Generic Business	 Expand the premium generics* business Obtain top 3 market share for day-1 launch products Pursue low cost operations 				
Vaccine Business	 Establish Daiichi Sankyo as a leading vaccine company Enhance the manufacturing/CMC structures and improve manufacturing efficiency Join national plan for human influenza pandemic 				
OTC Business	 Increase sales and improve P&L structure Maximize the "Loxonin S" brand Expand skin care direct marketing business 				







Transition to a Low-cost Operating Framework				
Theme	Mid-term Strategy			
Establish organizational structure to address diverse needs in each region	 Optimize organizational structures in every region Streamline support functions Substantially reduce SG&A expenses (approx. 10% reduction) 			
Establish global supply chain system for continuous cost reduction	 Cost reduction in Olmesartan and edoxaban API through collaboration with Ranbaxy Establish global procurement platform to benefit from scale Reorganization of API manufacturing facilities in Japa Overall reduction Target: Over 30 bn yen (cumulative) 			
Strengthen revenue management	 Strengthen revenue management at business- unit/regional/product level Strengthen cash flow management 			
	32			

